Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Keeping treatment going may help, but the data aren't definitive. A new study found that maintenance therapy after first-line bevacizumab-based chemo was linked to longer survival in metastatic colorectal cancer patients — but the advantage disappeared once researchers accounted for baseline differences between groups. The findings hint at a benefit, especially in higher-risk patients, but stop short of a clear recommendation.
Keeping treatment going may help, but the data aren't definitive. A retrospective study of 94 patients with metastatic colorectal cancer (mCRC) found that maintenance therapy — using capecitabine, bevacizumab, or a combination — was associated with longer overall survival (OS) compared to active surveillance after first-line bevacizumab-based chemotherapy. But here's the catch: once researchers adjusted for baseline prognostic factors, that survival edge faded away.
The unadjusted numbers looked promising — median OS of 24.8 months vs. 18.0 months in favor of maintenance — but the adjusted analysis told a more cautious story. Subgroup analyses did suggest potential benefits for patients with two or more metastatic sites or RAS-mutant tumors, though no interaction reached statistical significance.
By the Numbers:
Why it matters: The study adds real-world texture to an ongoing debate about post-induction treatment strategy in mCRC, but its retrospective, single-center design limits firm conclusions. Randomized trials are needed to settle the question.
